March 20 (Reuters) - Enlivex Therapeutics Ltd: * ENLIVEX RECEIVES POSITIVE DSMB RECOMMENDATION AND IMOH CLEARANCE TO CONTINUE PHASE I/II TRIAL OF ALLOCETRA COMBINED WITH CHEMOTHERAPY IN PATIENTS WITH
March 20 (Reuters) - Moonlake Immunotherapeutics : * REPORTS FOURTH QUARTER AND YEAR-END 2022 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE * TOP-LINE RESULTS FOR A PHASE 2 TRIAL OF SONELOKIMAB IN
March 20 (Reuters) - One Glove Group Bhd: * PROPOSES TO UNDERTAKE REVISED RENOUNCEABLE RIGHTS ISSUE OF 142 MILLION NEW SHARES AT ISSUE PRICE OF 0.22 RGT PER SHARE * REVISED ISSUANCE ON BASIS OF 1
March 20 (Reuters) - Orion Oyj: * DAROLUTAMIDE APPROVED FOR ADDITIONAL PROSTATE CANCER INDICATION IN CHINA * DAROLUTAMIDE IS ALREADY APPROVED IN CHINA FOR TREATMENT OF PATIENTS WITH NON-METASTATIC
March 20 (Reuters) - Fonet Bilgi Teknolojileri AS : * FONET BILGI TEKNOLOJILERI AS WINS TENDER WORTH 5.9 MILLION LIRA FROM TUNCELI PROVINCIAL HEALTH DIRECTORATE Source text for Eikon: Further company
March 20 (Reuters) - Hikma Pharmaceuticals PLC: * HIKMA - HIKMA LAUNCHES CEFAZOLIN FOR INJECTION, USP, IN THE US Further company coverage:
March 20 (Reuters) - The UK's anti-trust regulator said on Monday that hearing device maker Cochlear and Copenhagen-based Demant had denied that the Australian firm's purchase of Demant's hearing
March 20 (Reuters) - UK CMA: * UK'S CMA - DEMANT, COCHLEAR CONTEST CMA'S PHASE 1 FINDINGS THAT OTHER HEARING SOLUTIONS ARE NOT GOOD ALTERNATIVES FOR BONE CONDUCTION IMPLANTS * CMA - DEMANT, COCHLEAR
(Adds graphic, politician, academic) By Tom Sims and John Revill ZURICH, March 20 (Reuters) - Switzerland awoke to a new era on Monday after UBS swept up Credit Suisse in a government-brokered rescue
(Adds comment from Chinese ministry) March 20 (Reuters) - New Zealand's foreign minister, Nanaia Mahuta, will travel to China on Tuesday to meet her counterpart Qin Gang on the first such visit by a